We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 12,106.00 | 12,120.00 | 12,122.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 31.55 | 187.67B |
Hot Features
Premium
RNS Number:5546H
AstraZeneca PLC
17 February 2003
RESULTS OF EXANTA(TM) (ximelagatran) TRIAL IN PREVENTION OF STROKE IN ATRIAL
FIBRILLATION (SPORTIF III)
TO BE PRESENTED AT ACC MEETING
AstraZeneca announced today that headline results of the recently completed
SPORTIF III (Stroke Prevention Oral Thrombin Inhibitor in Atrial Fibrillation)
trial comparing ExantaTM (ximelagatran), with warfarin, the current standard of
care, are encouraging. The data support the emerging positive benefit / risk
profile for Exanta in this indication and will be presented in the Late-Breaking
Clinical Trial section of the American College of Cardiology (ACC) meeting in
Chicago on 2 April 2003.
The Exanta regulatory submission for prevention of stroke in atrial
fibrillation, which remains on track in Europe and the US, also includes SPORTIF
V and other trials in the extensive clinical trial programme.
Exanta is set to be the first new fixed-dose oral anticoagulant since the
introduction of warfarin over 50 years ago and is currently being investigated
in an extensive clinical trials programme for a number of key indications.
Exanta is a trademark, property of the AstraZeneca Group of Companies
For further information, please contact:
February 17, 2003
Media Enquiries:
Emily Denney, Tel: +44 (0) 207 304 5034
Steve Brown, Tel: +44 (0) 207 304 5033
Investor Relations:
Mina Blair Robinson, Tel: +44 (0) 207 304 5084
Jonathan Hunt, Tel: +44 (0) 207 304 5087
-Ends-
This information is provided by RNS
The company news service from the London Stock Exchange
END
RESEAKAXFLLDEEE
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
